A5007757182- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Helicobacter pylori-related gastroenterology studies
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Galectins and Cancer Biology
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Immune Response and Inflammation
- Sarcoma Diagnosis and Treatment
- Cytokine Signaling Pathways and Interactions
- Angiogenesis and VEGF in Cancer
- Neonatal Respiratory Health Research
- Cancer-related molecular mechanisms research
- IL-33, ST2, and ILC Pathways
- Advanced biosensing and bioanalysis techniques
- Axon Guidance and Neuronal Signaling
- Immune cells in cancer
- Gastric Cancer Management and Outcomes
- vaccines and immunoinformatics approaches
- Lung Cancer Treatments and Mutations
- Receptor Mechanisms and Signaling
University of Pennsylvania
2019-2023
Medical University of Vienna
2014-2018
Comprehensive Cancer Center Vienna
2014-2018
Inhibitors of the epidermal growth factor receptor (EGFR) are first-line therapy for patients with metastatic colorectal tumors without RAS mutations. However, EGFR inhibitors ineffective in these patients, and tumor level does not associate response to therapy. We screened human EGFR-positive myeloid cells investigated their association patient outcome. also performed studies mice evaluate how expression contributes development colitis-associated cancer Apc
Intestinal epithelial cells (IEC) have important functions in nutrient absorption, barrier integrity, regeneration, pathogen-sensing, and mucus secretion. Goblet are a specialized cell type of IEC that secrete Trefoil factor 3 (TFF3) to regulate viscosity wound healing, but whether TFF3-responsiveness requires receptor is unclear. Here, we show leucine rich repeat nogo-interacting protein 2 (LINGO2) essential for TFF3-mediated functions. LINGO2 immunoprecipitates with TFF3, co-localizes TFF3...
T cell receptor (TCR)-based immunotherapy has emerged as a promising therapeutic approach for the treatment of patients with solid cancers. Identifying peptide-human leukocyte antigen (pHLA) complexes highly presented on tumors and rarely expressed healthy tissue in combination high-affinity TCRs that when introduced into cells can redirect to eliminate tumor but not is key requirement safe efficacious TCR-based therapies. To discover shared antigens could be targeted via adoptive therapy,...
Natural killer (NK) cells are frequently expanded for the clinic using irradiated, engineered K562 feeder expressing a core transgene set of membrane-bound (mb) IL15 and/or mbIL21 together with 41BBL. Prior comparisons mbIL15 to NK expansion lack key attributes resulting cells, including their high-dimensional phenotype, polyfunctionality, breadth and potency cytotoxicity, cellular metabolism, activity in xenograft tumor models. Moreover, despite multiple rounds stimulation, studies...
Osteosarcoma (OS) is a rare tumor of the bone occurring mainly in young adults accounting for 5% all childhood cancers. Because limited therapeutic options, there has been no survival improvement OS patients past 40 years. The epidermal growth factor receptor (EGFR) highly expressed OS; however, its clinical relevance unclear. Here, we employed an autochthonous c-Fos-dependent mouse model (H2-c-fosLTR) and human biopsies preclinical studies aimed at identifying novel biomarkers benefits...
Abstract Success of immune checkpoint inhibitors (e.g., anti-PD1 antibodies) have revolutionized cancer immunotherapy by demonstrating that a patient’s own T-cells recognize and treat cancer. The efficacy PD-1 blockade is driven recruitment new from blood rather than via activation pre-existing tumor infiltrating lymphocytes (Yost K.E., et al. Nat. Med. 2019). However, therapy most effective in ~5% malignancies i.e., cancers with high mutational burden. Hence, the challenge addressing lower...
<h3>Background</h3> Success of immune checkpoint inhibitors, e.g., anti-PD1 antibodies have revolutionized cancer immunotherapy by demonstrating that a patient's own T-cells recognize and treat cancer. The efficacy PD-1 blockade is driven recruitment new from blood rather than via activation pre-existing tumor infiltrating lymphocytes.<sup>1</sup> However, therapy most effective in ~5% malignancies i.e., cancers with high mutational burden. Hence, the challenge addressing lower burden (the...
Abstract Constant exposure of intestinal epithelial cells (IEC) to potentially damaging stimuli makes mucosal repair programs essential for gut homeostasis, immunological quiescence and resistance colitis. Trefoil factor 2 (TFF2) is a mucus associated protein that promotes barrier integrity in the lung intestine, but whether bona-fide TFF2 receptor exists remains controversial. Herein, we provide evidence leucine rich repeat nogo interacting 3 (LINGO3) transmembrane component signaling...
Abstract T cell activation is an anabolic process requiring both large amounts of energy and biomaterials to construct daughter cells. We examined structural changes the mitochondria during activation, given its predominant role in generating ATP harboring key building blocks such as NADH. Upon massively disturb their cristae swell a that peaks after 48 hours. As cells begin rest down, we observed revert back pre-activation phenotype. Intriguingly environments limit have less disruption,...
<h3>Background</h3> Effective cancer therapy is still a challenge, and there strong need for remarkable therapeutic outcomes. Among the most compelling new approaches are targeted therapies, specialized vaccines (MTI, MVA),100-mer peptide, immune checkpoint blocking (ICI) antibodies association.<sup>1</sup> Our initial studies showed that established tumors in mice derived from tumor cell lines expressing tumor-associated form of MUC1 (TA-MUC1), cell-surface antigen presents tumor-specific...
<p>Figure S4. Expressions of the immune checkpoints on freshly isolated-NK cells and expanded-NK cells</p>
<p>Figure S7. Pearson correlation, heatmap, and GSEA analysis of Bulk RNA-Seq data</p>
<div>Abstract<p>Natural killer (NK) cells are frequently expanded for the clinic using irradiated, engineered K562 feeder expressing a core transgene set of membrane-bound (mb) IL15 and/or mbIL21 together with 41BBL. Prior comparisons mbIL15 to NK expansion lack key attributes resulting cells, including their high-dimensional phenotype, polyfunctionality, breadth and potency cytotoxicity, cellular metabolism, activity in xenograft tumor models. Moreover, despite multiple rounds...
<p>Figure S6. Isoplexis-tSNE plots and polyfunctionality heatmap of single-cell secretome</p>
<p>Figure S6. Isoplexis-tSNE plots and polyfunctionality heatmap of single-cell secretome</p>
<div>Abstract<p>Natural killer (NK) cells are frequently expanded for the clinic using irradiated, engineered K562 feeder expressing a core transgene set of membrane-bound (mb) IL15 and/or mbIL21 together with 41BBL. Prior comparisons mbIL15 to NK expansion lack key attributes resulting cells, including their high-dimensional phenotype, polyfunctionality, breadth and potency cytotoxicity, cellular metabolism, activity in xenograft tumor models. Moreover, despite multiple rounds...
<p>Figure S2. Representative flow plots of SSA against FSA and the expression CD56 CD3 NK 2 cells as well gating strategy for counting cells</p>
<p>Figure S7. Pearson correlation, heatmap, and GSEA analysis of Bulk RNA-Seq data</p>
<p>Figure S5. Statistical analysis of the cytotoxicity expanded-NK cells against different tumor targets and their degranulation.</p>
<p>Figure S3. Expressions of activating receptors and cell death ligands on freshly isolated-NK cells 2 expanded-NK cells.</p>
<p>Figure S1. mbIL-21 structure and the effect of K562 expressing CD40 on NK cell expansion</p>
<p>Figure S1. mbIL-21 structure and the effect of K562 expressing CD40 on NK cell expansion</p>